E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

NCT01332266 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: E7050
DRUG: Cetuximab

Sponsor

Eisai Inc.

Collaborators

[object Object]